Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2015
Price : $35 *
At a glance
- Drugs Clopidogrel (Primary) ; Ticagrelor (Primary)
- Indications Acute coronary syndromes
- Focus Pharmacodynamics; Pharmacogenomic
- 31 Aug 2018 Biomarkers information updated
- 01 Dec 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 27 May 2015 Planned End Date changed from 1 Dec 2014 to 1 Oct 2015, according to ClinicalTrials.gov record.